Optimizing Frontline TKI Therapy in Advanced uHCC: Managing Adverse Events
An expert discusses how in the first-line (1L) treatment of advanced unresectable hepatocellular carcinoma (uHCC) with tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib, proactive adverse event (AE) management is crucial. This includes baseline assessment; regular monitoring of adverse effects such as hypertension, hand-foot syndrome, and fatigue; and implementing preventive strategies. Treatment should be individualized with dose modifications as needed to balance therapeutic efficacy with quality of life, particularly given the advanced disease state.
Video content above is prompted by the following:
- When using systemic TKI as 1L treatment in advanced uHCC, what are important considerations during treatment implementation?
- What are common AEs seen with the use of lenvatinib or sorafenib?
- What is your approach to AE prevention, monitoring, and management?
- What strategies can be implemented to address toxicity profiles with either therapy?
- How do you balance treatment intensity/goals with maintaining quality of life, especially when patients have advanced-stage disease?
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
